drugset / Trial / NCT06940518
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Phase 2
Recruiting
40 enrolled
M.D. Anderson Cancer Center
Strategic Alliance · collabSummit Therapeutics · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ccRCC.
Timeline
- Start
- 2025-07-02
- Primary completion
- 2028-01-19
- Completion
- 2030-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivonescimab | Monoclonal antibody | — | Intravenous |